Delivra Health Brands Announces Closing of Non-Brokered Private Placement of Units

In This Article:

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2023) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company uniquely positioned in the health and wellness sector, is pleased to announce the closing of its non-brokered private placement (the "Offering") of units (the "Units") previously announced on December 1, 2023. The Company issued a total of 60,000,000 Units at a price of $0.015 per Unit for aggregate gross proceeds of $900,000. Each Unit is comprised of one common share of the Company ("Common Share") and one Common Share purchase warrant (each, a "Warrant"). Each Warrant will entitle the holder thereof to acquire one Common Share (each, a "Warrant Share") at a price of $0.05 per Warrant Share for 36 months following the completion of the Offering.

The Company intends to use the net proceeds of the Offering for working capital and general corporate purposes and to support its ongoing marketing initiatives to support its distribution and customer acquisition strategy. All securities issued pursuant to the Offering are subject to a hold period of four months plus a day from the date of issuance prescribed by the TSX Venture Exchange (the "TSX-V") and the resale rules of applicable securities legislation. In connection with the Offering, the Company incurred cash finder's fees of $18,459 on gross proceeds raised by eligible arm's length parties.

Certain insiders of the Company (the "Insiders") participated in the Offering and acquired an aggregate of 35,820,000 Units. Such subscriptions by the Insiders constitute a related party transaction under Multilateral Instrument 61-101 - Protection of Security Holders in Special Transactions ("MI 61-101"). However, any such purchase is exempt from the formal valuation and minority approval requirements of MI 61-101 by virtue of the exemptions contained in sections 5.5(b) and 5.7(1)(b) of MI 61-101, and where there is no other requirement, corporate or otherwise, to hold a meeting to obtain any approval of the holders of any class of affected securities. Pursuant to MI 61-101, the Company will file a material change report providing disclosure in relation to each "related party transaction" on SEDAR+ under Delivra Health's issuer profile at www.sedarplus.ca. The Company did not file a material change report more than 21 days before the expected closing date of the Offering as required by MI 61-101, because the timing of the announcement and the closing date was less than 21 days apart.